Neoadjuvant therapy gains FDA approval in non-small cell lung cancer
Ticiana Leal, Suresh S. Ramalingam
Abstract
Forde et al.1Forde P.M. Spicer J. Lu S. Provencio M. Mitsudomi T. Awad M.M. Felip E. Broderick S.R. Brahmer J.R. Swanson S.J. et al.Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer.N. Engl. J. Med. 2022; 386: 1973-1985https://doi.org/10.1056/nejmoa2202170Crossref PubMed Scopus (0) Google Scholar reported on a randomized clinical trial (CheckMate 816) and showed that neoadjuvant therapy with nivolumab plus chemotherapy led to improved event-free survival and pathological complete response rate in patients with resectable non-small cell lung cancer (NSCLC).
Topics & Concepts
MedicineLung cancerDrug approvalOncologyMedical physicsIntensive care medicinePharmacologyDrugLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentCancer Genomics and Diagnostics